Background and Aim: T cells are key players in the chronic intestinal inflammation that characterises Crohn's disease. Here we aim to map the intestinal T-cell receptor [TCR] repertoire in patients with Crohn's disease, using next-generation sequencing technology to examine the clonality of the T-cell compartment in relation to mucosal inflammation and response to therapy. Methods: Biopsies were taken from endoscopically inflamed and uninflamed ileum and colon of 19 patients with Crohn's disease. From this cohort, additional biopsies were taken after 8 weeks of remission induction therapy from eight responders and eight non-responders. Control biopsies from 11 patients without inflammatory bowel disease [IBD] were included. The TCRβ repertoire was analysed by next-generation sequencing of biopsy RNA. Results: Both in Crohn's disease patients and in non-IBD controls, a broad intestinal T-cell repertoire was found, with a considerable part consisting of expanded clones. Clones in Crohn's disease were more expanded [p = 0.008], with the largest clones representing up to as much as 58% of the total repertoire. There was a substantial overlap of the repertoire between inflamed and uninflamed tissue and between ileum and colon. Following therapy, responders showed larger changes in the T-cell repertoire than non-responders, although a considerable part of the repertoire remained unchanged in both groups.
Introduction
Several human and murine studies have implicated T cells as key mediators of the chronic intestinal inflammation that characterises inflammatory bowel disease [IBD] . 1 Large numbers of T cells accumulate in the intestine as a result of enhanced recruitment of guthoming T cells 2 and local proliferation and survival. 3, 4 A decline in the number of T-cells, for example during HIV infection, has been associated with amelioration of disease. 5 Therapeutic approaches that directly or indirectly target T cells are used in the management of Crohn's disease. The latter include the anti-IL-12/23 p40 antibody ustekinumab, 6, 7 which interferes with the expansion and maintenance of inflammatory Th17 cells, 8 and also the integrin α4β7-blocking antibody vedolizumab, [9] [10] [11] which blocks the migration of gut-homing effector T cells. In fact, even the therapeutic effect of the more conventional immunosuppressant azathioprine was found to be largely attributable to the induction of T-cell apoptosis. 12 Crohn's disease patients who fail therapy or develop complications will undergo resection of the inflamed bowel parts-putatively along with a local pathogenic T-cell compartment. Although surgery greatly improves the quality of life in these patients, a majority will experience disease relapse and require further surgery. 13 In Crohn's disease, T cells participate in what is considered an excessive immune response against luminal antigens which would normally be tolerated. Conventional αβ T cells-the majority of T cells in the gut-specifically recognise antigens by virtue of their heterodimeric αβ T-cell receptor [TCR] . 14 Once T cells encounter their cognate antigen, they may proliferate to produce a clone of TCR-identical cells. With the intestinal mucosa being continuously exposed to environmental antigens, such encounters are ubiquitous and they are considered a major determinant of the intestinal T-cell clonal landscape.
Earlier studies demonstrated that before birth, seeding of T cells to the gut occurs randomly. Subsequently, the repertoire is shaped by the intestinal microenvironment. [15] [16] [17] [18] In conditions of chronic intestinal inflammation like Crohn's disease, the TCR repertoire is thought to be more profoundly skewed due to excessive immune responses against luminal antigens. Several studies have observed increased oligoclonal T-cell expansions in IBD mouse models as well as in the blood and inflamed mucosa of IBD patients. 19, 20 This might suggest an important role for dominant T-cell clones in the pathogenesis of Crohn's disease.
Here, we use a next-generation sequencing [NGS]-based approach 21 to investigate the clonality of the intestinal TCR beta repertoire in Crohn's disease patients and in non-IBD controls, aiming to map quantitatively the spatial and temporal repertoire differences. We show that a fairly stable T-cell repertoire with profound expansions is present and maintained in the intestine of Crohn's disease patients regardless of the endoscopic presence of mucosal inflammation, and is comparable between different anatomical sites. Even though response to treatment is associated with a more substantial change in the T-cell repertoire over time, a considerable part of the repertoire persists even in responders.
Methods

Study subjects
Between 2009 and 2013, we prospectively collected endoscopic biopsies from a cohort of 40 patients with Crohn's disease. All patients were diagnosed with Crohn's disease before inclusion based on standard endoscopic and histological criteria. Eleven patients were excluded due to treatment strategies other than remission induction, such as surgery, dose escalation, or the start of immunomodulators. A total of 29 patients started remission induction therapy by adalimumab [160 mg-80 mg-40 mg every 2 weeks], infliximab [5 mg/kg at 0, 2, and 6 weeks], and/or budesonide [9 mg daily]. Four patients stopped treatment prematurely due to adverse events. Response to remission induction therapy was assessed in 25 patients. Currently the most objective markers reflecting Crohn's disease activity and the response to treatment include CRP levels and endoscopic assessment of mucosal inflammation, usually with an endoscopic index such as the Crohn's Disease Endoscopic Index of Severity [CDEIS] . Both were assessed before and 8 weeks after the start of remission induction therapy. Response was defined as an improvement in CDEIS of at least 20% in conjunction with normalisation of CRP levels [< 5.0 mg/l]. Non-response was defined as a lack of improvement in CDEIS and CRP levels. Ten and nine patients, respectively, fulfilled the criteria for response and non-response at 8 weeks of follow-up, of which paired follow-up samples of eight responders and eight nonresponders passed quality control requirements for TCR sequence analysis. An additional three patients were included from whom both ileal and colonic [endoscopically] inflamed and uninflamed tissue was available [see Table 1 for patient characteristics]. Uninflamed control tissue was collected from eleven patients undergoing surgery unrelated to IBD, which mainly involved resection of adeno[carcino]mas of the colon [ Table 2 ]. Control patients were excluded when undergoing chemo-or radiotherapy before resection. The study protocols were approved by the Medical Ethical Committee of the Academic Medical Center, Amsterdam, The Netherlands, and all participants gave written informed consent.
Gut tissue sampling and processing
Biopsies were collected during endoscopy before and 8 weeks after initiating remission induction. Biopsy sampling was performed from the most inflamed part of the ileum or colon, depending on the localisation of disease activity. When ulcers were present, biopsies were taken from the edge of the ulcer avoiding necrotic tissue. When uninflamed ileum and colon were present, additional biopsies were obtained, preferably near inflamed areas. Control tissue was isolated from resection specimens of patients without IBD, if applicable at several centimetres distance from the adeno[carcino] ma. Immediately after harvesting, all tissues were stored in RNAlater Stabilization Reagent [#76104, Qiagen, Venlo, The Netherlands] and transported to the laboratory, where they were stored at −80°C. Isolation and quantification of RNA, and cDNA synthesis, were performed as described previously. 21 
Linear amplification and NGS
The linear amplification protocol has been extensively described earlier. 21 Samples were prepared for sequencing according to the manual for Amplicon Sequencing, and sequenced on a Roche Genome Sequencer FLX [Titanium platform]. For each sample, 5000 TCRβ sequences were analysed.
NGS bioinformatics pipeline and data analysis
The bioinformatics pipeline was described previously in detail 21 
Results
To study T-cell clones in the gut of patients with Crohn's disease and compare them with intestinal tissue of patients without IBD, we set out to analyse the TCR repertoire in endoscopically inflamed and uninflamed ileum and colon from untreated patients with Crohn's disease, as well as non-inflamed ileum and colon from [non-IBD] controls [details described in Table 1 . We found that in controls, T-cell clones were expanded up to a maximum of 9.4% of the total repertoire [dashed grey lines, Figure 1A -C], whereas in Crohn's disease patients, T-cell clones were more expanded, especially in uninflamed tissue [p = 0.008, Figure 1D ]. In conclusion, this showed that the intestinal T-cell repertoire in patients with Crohn's disease contains remarkably large clones that are not found in controls-notably clones representing about 30%, 40%, and even 60% of the total repertoire. Subsequently we analysed to what extent inflamed and uninflamed gut tissue share the same T-cell clones. To this end, we compared within patients the whole repertoire of individual T-cell clones present in inflamed and uninflamed tissue, in both ileum and colon [ Figure 2A -N]. On average, 363 clones were shared between inflamed and uninflamed tissue, in a total repertoire of 2342 T-cell clones [mean 15.5%, SD 6.5%, Figure 2O ]. Taking the size of the clones into account, 36.5% [mean, SD 16 .2%] of the TCR repertoire was shared between inflamed and uninflamed tissue [ Figure 2P ], and this was observed in both ileum and colon. When we selectively looked at the overlap of clones above a certain size by introducing different cut-off values of clonal frequency [1st, 5th, 10th, 25 th , and 50th percentile], we found a similar overlap in the most dominant part of the repertoire [ Supplementary Figure 2 , available at ECCO-JCC online]. These findings raised the question whether TCR repertoires at anatomically different tissue sites, ileum and colon, are shared as well. This comparison showed an overlap of 9.5% of the TCR clones in ileum and colon, together taking up 28.6% of the total TCR repertoire [ Figure 3 ]. This was observed in both inflamed and uninflamed tissue and again was comparable when using different cut-offs to look at overlap [Supplementary Figure 3 , available at ECCO-JCC online]. Together, these analyses showed that about onethird of the repertoire was shared between inflamed an uninflamed tissue as well as between colon and ileum.
Finally, we studied whether successful treatment results in a loss of intestinal T-cell clones initially present in the inflamed tissue. To this end, paired biopsies before and 8 weeks after start of therapy in 16 patients were analysed, which fulfilled the criteria for Together, these findings showed that successful treatment resulted in a more substantial change in the T-cell repertoire over time, especially within clonally expanded T cells. In spite of that, however, also in responders still a considerable part of the repertoire persisted.
Discussion
The present work provides the first next-generation sequencing-based analysis of the T-cell repertoire in the human intestine, quantitatively uncovering the clonal landscape of the intestinal T-cell compartment in patients with Crohn's disease and in controls. It revealed that the intestinal T-cell repertoire of patients with Crohn's disease contains profound expansions and is remarkably stable between inflamed and uninflamed mucosa and between ileum and colon. Successful treatment did result in a loss of some of the expanded clones compared with patients who did not respond to therapy, but there was still a considerable overlap and some large expansions persisted also in responders.
A comparison of patients with Crohn's disease and controls showed that clonal expansions are common in the intestine of both groups, yet with remarkably large expansions exclusively present in patients with Crohn's disease. This is consistent with earlier studies which, using more traditional methods such as CDR3 spectratyping, reported increased expansions and skewing of T cells in patients with Crohn's disease 19, 20 and in different mouse models including the CD4 + CD45RB hi adoptive transfer model. 22 Our observations also agree with a very recent NGS-based repertoire analysis in Crohn's disease by Chapman et al. who detected mucosal T-cell expansions of a similar order of magnitude. 23 The expansions that we observed in patients with Crohn's disease-some representing as much as 30%, 40%, and even about 60% of the repertoire-are highly suggestive of the occurrence of excessive T-cell responses that characterise the disease and hint at the involvement of a limited number of dominant antigens in the pathogenesis of Crohn's disease, although it cannot be excluded that other factors such as higher TCR affinity and/or cellular fitness [e.g. cell-intrinsic changes conferring a proliferative and/or survival advantage] play a role in the apparent selective expansion of clones. Whereas a valid concern for biopsy studies is that measurements may not be representative of the surrounding tissue area, we found considerably overlapping repertoires in multiple biopsies from different sites in ileum and colon, in both inflamed and uninflamed tissue and at baseline as well as in follow-up samples. This indicates that many of the dominant clones found in biopsies are in fact more than just a snapshot of a given time and place, strengthening the idea that these are of relevance and might even be pathogenic. However, even though it is tempting to interpret these clones as disease-specific clones, their pathogenicity needs to be evaluated in terms of phenotype and function.
Although the overlap of the whole T-cell repertoire in paired Crohn's disease samples from inflammatory lesions and endoscopically uninflamed areas might argue against a relation between the repertoire and disease, it is well known that inflammatory activity can be present in mucosa assessed as normal on endoscopy, a notion that is consistent with the high rates of postoperative disease relapse observed in patients with Crohn's disease. 13 Interestingly, more clonal expansions were present in endoscopically uninflamed compared with inflamed tissues, which raises the possibility that the local appearance of dominant clones may even precede full-blown disease activity. Similar dynamics have been reported for rheumatoid arthritis where the strongest clonal dominance of both T and B cells in the synovium was observed in the earliest phase of disease, 24, 25 and for multiple sclerosis where the appearance of clonal B cells in the cerebrospinal fluid appeared to be an early event in the inflammatory process in the central nervous system. 26 The presence of large T-cell expansions in endoscopically uninflamed mucosa might hence be predictive of future [relapse of] inflammation, as was previously proposed for the presence of CD4 + NKG2D + T-cell clones at the noninflamed edge of the surgical specimen. 20 Biopsies taken after therapeutic intervention provided the unique opportunity to investigate whether the success of induction therapy with current standard medication was related to changes in the T-cell repertoire. Indeed, a loss of certain expanded clones was seen in patients with Crohn's disease responding to therapy whereas this was not observed in non-responders. However, a substantial part of the repertoire persisted after 8 weeks of successful therapy. It is plausible that a therapeutic response, at least to these current standard drugs, may not be associated so much with changes in the T-cell repertoire per se, but rather with changes in the activity and possibly size of the repertoire, e.g. through suppression of T-cell activation/ proliferation, recruitment, or by partial induction of T-cell death. Importantly, if inhibition rather than eradication of a pathogenic T-cell repertoire is implicated in the response to treatment, its quiescent presence in situ might explain why the tissue remains prone to disease relapse. It is tempting to speculate that more profound repertoire changes, i.e. 'resetting' of the local T-cell compartment, are required to effectively induce permanent remission. Currently 50% of Crohn's disease patients who cease anti-TNF therapy experience a disease relapse at 12 months after stopping therapy. 27 It would be of interest to investigate whether patients with the smallest compression of the T-cell repertoire over therapy are at highest risk of disease relapse after withdrawal of therapy. Finally, the suggested involvement of the recently discovered subset of tissue-resident memory T cells, which may persist for decades at peripheral tissues without recirculating, 28 may present a relapse-prone population that forms the stable repertoire that we observe and that, with current therapies, is simply not effectively targeted.
In conclusion, this is the first NGS-based analysis of the T-cell gut repertoire in Crohn's disease mapping spatial and temporal repertoire differences. The striking alterations in repertoire distribution in Crohn's disease, the substantial overlap in T-cell repertoire between inflamed and uninflamed ileum and colon, and the finding that a substantial part of the T-cell repertoire persists despite successful treatment, warrants further investigation into the nature of clonal T-cell expansions as well as identification of the [groups of] antigens that trigger these responses. This may in time lead to development of more targeted treatment options for Crohn's disease.
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